7412: Survey on cardiovascular events in patients with metabolic disease on chronic carnitine supplementation

This study consists of an online survey developed by researchers from the North American Mitochondrial Disease Consortium and sent to those enrolled in the RDCRN Contact Registry.

This Study is for:

Alpers syndrome
Aminoglycoside-induced deafness
Barth syndrome
Carnitine transporter defects
Cardiomyopathy
Complex I deficiency
Complex II deficiency
Complex III deficiency
Complex IV deficiency
Complex V deficiency
CPEO
CPEO "plus"
Diabetes & deafness
Encephalomyopathy
Hepatocerebral syndrome
Kearns-Sayre syndrome
Leigh syndrome
Leber hereditary optic neuropathy (LHON)
Leukoencephalopathy
Maternal-inherited deafness
MELAS
MERRF
MNGIE
MIRAS
Mitochondrial depletion
Myopathy
NARP
Pearson syndrome
Reversible infantile myopathy with cytochrome c oxidase deficiency
SANDO
Pyruvate dehydrogenase deficiency
Pyruvate carboxylase deficiency
Coenzyme Q10 deficiency
Other: Any fatty acid oxidation disorder, organic academia and any well defined metabolic disorder.

Summary

Background

The purpose of this study is to learn more about the use of the supplement carnitine in patients with mitochondrial and metabolic disorders. Individuals with mitochondrial disease or any other metabolic disorder who are taking carnitine or who have been on carnitine within the last 12 months may take part in the study.

This study is no longer recruiting patients.